Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Changsha Innovative Traditional Chinese Medicine Modernization Research Institute is a specialized R&D entity based in Hunan, China, focused on the scientific advancement and standardization of Traditional Chinese Medicine (TCM). Led by Professor Zeng Jianguo, the institute specializes in the extraction and application of bioactive compounds from medicinal plants, most notably Macleaya cordata. Its work spans human pharmaceuticals, veterinary medicines, and natural feed additives, aiming to replace antibiotics with plant-derived alternatives. The institute plays a pivotal role in the TCM modernization movement by integrating ethnobotany with modern pharmacological screening and quality control standards. It maintains strong academic ties with Hunan Agricultural University and serves as the research core for several commercial biotech spin-offs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changsha Innovative Traditional Chinese Medicine Modernization Research Institute.